News

Recordati has acquired worldwide rights over Novartis‘ investigational therapy osilodrostat (LCI699), being developed for the treatment of endogenous Cushing’s disease. The agreement also covers Signifor (pasireotide), an approved treatment for adults with Cushing’s disease who failed surgery or who were not eligible for surgery,…

A new international consortium based in Paris, and funded largely by the 28-member European Union, intends to speed the diagnosis of rare diseases, while also accelerating the development of treatments for the 95% of such illnesses that currently don’t have one. The European Joint Programme on Rare Diseases (EJP…

Tumors in the thymus that produce too much of the adrenocorticotropic hormone (ACTH) may be the cause of ectopic Cushing’s syndrome, a case report shows. ACTH staining may be useful to confirm ACTH production in suspicious tumors, researchers said. The study, “Ectopic Cushing’s syndrome due to adrenocorticotropic hormone secreting…

Cases of adrenocorticotropic hormone (ACTH)-independent Cushing’s syndrome are often caused by unilateral tumors in the adrenal glands, but Indian researchers have now reported a rare case where the condition was caused by tumors in both adrenal glands. Fewer than 40 cases of bilateral tumors have been reported so far, but…

A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by…